1478-1479 / 2437
Conclusion
•
The ACNS1221 regimen without IT MTX failed to achieve the
desirable 2y PFS of 90%, leading to premature closure of the
study
•
None of the MBEN and of the patients under 12 months
relapsed
•
The molecular characterization of this ND/MBEN cohort is
currently been investigated and may help uncover patients
who may still benefit from this regimen
Lucie Lafay-Cousin ASCO meeting Chicago June 03rd 2017